IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow

Results to be announced at 8:00 a.m. Eastern time, conference call to begin at 8:30 a.m. Eastern time...

IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

Novel IL-12 Immunotherapy Administered with Standard of Care as First-Line Treatment Expects topline results...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 3 - Initial statement of beneficial ownership of securities

First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial

DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform LAWRENCEVILLE, N.J., June...

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

Form S-3 - Registration statement under Securities Act of 1933